Table 2.
Study | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Akbari et al. (2006) [33] | - | Yes | No | Yes | No | No | Yes | No | No | Yes | Yes | 5 |
Coroian et al. (2018) [29] | - | Yes | No | Yes | No | No | Yes | Yes | Yes | Yes | Yes | 7 |
Dehno et al. (2021) [30] | - | Yes | Yes | Yes | No | No | Yes | Yes | No | Yes | Yes | 7 |
Fernandes et al. (2015) [32] | - | No | No | No | No | No | No | Yes | No | No | Yes | 2 |
Fernandez et al. (2016) [34] | - | Yes | No | Yes | No | No | Yes | Yes | No | Yes | Yes | 6 |
Flansbjer et al. (2008) [35] | - | Yes | No | Yes | No | No | No | Yes | Yes | Yes | No | 5 |
Mun et al. (2019) [36] | - | Yes | No | Yes | No | No | No | No | No | Yes | Yes | 4 |
Lattouf et al. (2021) [37] | - | Yes | No | Yes | No | No | No | No | No | Yes | Yes | 4 |
Patten et al. (2013) [31] | - | Yes | Yes | Yes | No | No | Yes | Yes | No | Yes | Yes | 7 |
Range: 0–10. Item 1 is not used in the method score. Item 1: Eligibility criteria; Item 2: Random allocation; Item 3: Concealed allocation; Item 4: Baseline similarity; Item 5: Subject blinding; Item 6: Therapist blinding; Item 7: Assessor blinding; Item 8: >85% follow-up; Item 9: Intention-to-treat analysis; Item 10: Between-group statistical comparison; and Item 11: Point and variability measures.